It was therefore suggested to connect obesity-associated comorbidities, especially insulin resistance (IR), and certain components of the metabolic syndrome such as nonalcoholic fatty liver disease (NAFLD), in either retinol-dependent or retinol-independent way, with RBP4 [4,5]. Here, RBP4 is linked to metabolic dysfunction-associated steatotic liver disease.